Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Cardiovascular disease is "unacceptably" high and increasing among American adults ages 20 to 44, requiring aggressive prevention.
Read Full NewsAs part of NeurologyLive®'s Year in Review 2025, we've compiled some notable trials that began in 2025.
The director of the Pediatric Epilepsy Center at UCSF reviewed recently presented interim phase 1/2 data for ETX101, a one-time AAV9 gene regulation therapy aiming to increase SCN1A expression in inhibitory interneurons in Dravet syndrome.
As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews regarding multiple sclerosis in 2025.
Hidradenitis Suppurativa in 2025: Year in Review
1.
Cancer research in the US is world class. With the government pulling out, its future is uncertain
2.
Could AI plus lasers help catch very early breast cancers?
3.
New PET tracer enables same-day imaging of triple-negative breast and urothelial cancers
4.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
5.
A pilot study investigates a novel strategy for lowering anxiety and enhancing post-stem cell transplant quality of life.
1.
Unraveling the Genetic Mystery of Hereditary Spherocytosis
2.
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage
3.
Uncovering the Mysteries of Breast Cancer: The Journey to a Cure
4.
A New Hope: How Procarbazine is Revolutionizing Cancer Treatment
5.
Precision Medicine and Genomics: Harnessing Longitudinal Data Modeling to Decode Cancer Progression
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
2.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I
4.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge